Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results

There is a critical need for effective treatments for leptomeningeal disease (LMD). Here, we report the interim analysis results of an ongoing single-arm, first-in-human phase 1/1b study of concurrent intrathecal (IT) and intravenous (IV) nivolumab in patients with melanoma and LMD. The primary endp...

Descripción completa

Detalles Bibliográficos
Autores principales: Glitza Oliva, Isabella C., Ferguson, Sherise D., Bassett, Roland, Foster, Alexandra P., John, Ida, Hennegan, Tarin D., Rohlfs, Michelle, Richard, Jessie, Iqbal, Masood, Dett, Tina, Lacey, Carol, Jackson, Natalie, Rodgers, Theresa, Phillips, Suzanne, Duncan, Sheila, Haydu, Lauren, Lin, Ruitao, Amaria, Rodabe N., Wong, Michael K., Diab, Adi, Yee, Cassian, Patel, Sapna P., McQuade, Jennifer L., Fischer, Grant M., McCutcheon, Ian E., O’Brien, Barbara J., Tummala, Sudhakar, Debnam, Matthew, Guha-Thakurta, Nandita, Wargo, Jennifer A., Burton, Elizabeth M., Tawbi, Hussein A., Davies, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115650/
https://www.ncbi.nlm.nih.gov/pubmed/36997799
http://dx.doi.org/10.1038/s41591-022-02170-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115650/
https://www.ncbi.nlm.nih.gov/pubmed/36997799
http://dx.doi.org/10.1038/s41591-022-02170-x

Ejemplares similares